
AKBA • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold AKBA in your mock portfolio yet.
Akebia Therapeutics remains unprofitable, as indicated by its negative EPS and PE ratio. While the loss per share (-0.08) is not extremely large on an absolute basis, the negative valuation metrics underscore ongoing earnings risk and dependence on future pipeline or regulatory milestones. Without clear evidence of a near‑term profitability inflection, the financial profile leans negative for equity holders.
The stock trades at $1.45, down 9.9% over the last month and well below its 200‑day moving average of $2.65, indicating a pronounced downtrend. An RSI of 27.54 signals the shares are in oversold territory, which can lead to short‑term bounces but typically reflects sustained selling pressure. Overall, the technical setup is weak, with the primary trend still negative despite the possibility of tactical oversold rallies.
Alternative data for Akebia Therapeutics is mixed but not strongly positive. Modest web traffic (about 9,079 visitors per month) and relatively flat social media growth suggest limited retail or patient‑facing engagement momentum. However, a 16.7% month‑over‑month increase in job openings and steady LinkedIn growth point to some underlying operational activity and hiring, which can be consistent with ongoing development or commercialization efforts.
Overall, Akebia Therapeutics’ setup skews bearish: the stock is in a clear downtrend, trading well below its 200‑day moving average, and the company remains unprofitable. While oversold technicals and modest hiring growth could support short‑term stabilization or tactical rebounds, they do not yet offset the weak earnings profile and negative price momentum.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: